Monitoring PCDM-specific biomarkers, galectin-3S100A9, to serve as a risk assessment of pancreatic cancer on new-onset diabetes patients for early detection of PC.

Pancreatic cancer is a highly regarded cancer type with five-year survival rate of ~5. Most of the patients were diagnosed at the late stage of the disease. The importance of our research is the discovery of two novelspecific PCDM biomarkers, galectin-3S100A9, which make a critical breakthrough toward early diagnosis of pancreatic cancer.

To develop high sensitivityaccuracy galectin-3S100A9 diagnostic platform for pancreatic cancer early detection in specific new-onset diabetes patients.

天使投資人、策略合作夥伴